Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Reference-Cited by-同舟云学术

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease

Published:2024-05-23 Issue:1 Volume:60 Page:101-102
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Alahmad Maryam¹,Quraishi Mohammed Nabil¹,Khan Shaima Wasim¹,Omar Nadeen Mamon¹,Malik Talha A.¹²

Affiliation:

1. Department of Gastroenterology Sheikh Shakhbout Medical City Abu Dhabi United Arab Emirates

2. Department of Gastroenterology Mayo Clinic Arizona Phoenix Arizona USA

Abstract

LINKED CONTENTThis article is linked to Yiu et al papers. To view these articles, visit https://doi.org/10.1111/apt.18006 and https://doi.org/10.1111/apt.18057

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18049

Reference8 articles.

1. Meta‐analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease;Yiu TH;Aliment Pharmacol Ther,2024

2. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

3. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

4. DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

5. DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease—Authors' reply;Alimentary Pharmacology & Therapeutics;2024-05-23